Turning Receptors On and Off with Intracellular Pepducins: New Insights into G-protein-coupled Receptor Drug Development
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
G-protein-coupled receptors (GPCRs) are a large family of remarkably versatile membrane proteins that are attractive therapeutic targets because of their involvement in a vast range of normal physiological processes and pathological diseases. Upon activation, intracellular domains of GPCRs mediate signaling to G-proteins, but these domains have yet to be effectively exploited as drug targets. Cell-penetrating lipidated peptides called pepducins target specific intracellular loops of GPCRs and have recently emerged as effective allosteric modulators of GPCR activity. The lipid moiety facilitates translocation across the plasma membrane, where pepducins then specifically modulate signaling of their cognate receptor. To date, pepducins and related lipopeptides have been shown to specifically modulate the activity of diverse GPCRs and other membrane proteins, including protease-activated receptors (PAR1, PAR2, and PAR4), chemokine receptors (CXCR1, CXCR2, and CXCR4), sphingosine 1-phosphate receptor-3 (S1P3), the melanocortin-4 receptor, the Smoothened receptor, formyl peptide receptor-2 (FPR2), the relaxin receptor (LGR7), G-proteins (Gα(q/11/o/13)), muscarinic acetylcholine receptor and vanilloid (TRPV1) channels, and the GPIIb integrin. This minireview describes recent advances made using pepducin technology in targeting diverse GPCRs and the use of pepducins in identifying potential novel drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637 · cited 3×
“A specific cholesterol-binding site was observed in proximity to a conserved tryptophan residue from TM4 present in a large number of Class A members, suggesting a potential functional role in receptor binding and thermal stability (9).”
BackgroundFredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Crystal structure of opsin in its G-protein-interacting conformation
Scheerer, P., Park, J. H., Hildebrand, P. W., Kim, Y. J., Krauß, N., Choe, H.-W., Hofmann, K. P., & Ernst, O. P. (2008) · Nature · doi:10.1038/nature07330 · Cited by 1,059 · cited 2×
“The crystal structure of opsin (11, 12), the first example of an activated GPCR, indicates that the cytoplasmic loopsmove upon receptor activation.”
BackgroundAnnaházi, A., Gecse, K., Dabek, M., Ait-Belgnaoui, A., Rosztóczy, A., Róka, R., Molnár, T., Theodorou, V., Wittmann, T., Bueno, L., et al. (2009) · Pain · doi:10.1016/j.pain.2009.04.017 · Cited by 112
Luminal Cathepsin G and Protease-Activated Receptor 4
Dabek, M., Ferrier, L., Roka, R., Gecse, K., Annahazi, A., Moreau, J., Escourrou, J., Cartier, C., Chaumaz, G., Leveque, M., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080986 · Cited by 73
Slofstra, S. H., Bijlsma, M. F., Groot, A. P., Reitsma, P. H., Lindhout, T., ten Cate, H., & Spek, C. A. (2007) · Blood · doi:10.1182/blood-2007-02-075440 · Cited by 66
Cited by
Cell-Penetrating Peptides: From Basic Research to Clinics
Guidotti, G., Brambilla, L., & Rossi, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.01.003 · Cited by 1,147
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents
Borrelli, A., Tornesello, A., Tornesello, M., & Buonaguro, F. (2018) · Molecules · doi:10.3390/molecules23020295 · Cited by 295
G Protein–Coupled Receptor Signaling Through β-Arrestin–Dependent Mechanisms
Jean-Charles, P.-Y., Kaur, S., & Shenoy, S. K. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000482 · Cited by 280
The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition
He, H.-Q., & Ye, R. (2017) · Molecules · doi:10.3390/molecules22030455 · Cited by 279
Quoyer, J., Janz, J. M., Luo, J., Ren, Y., Armando, S., Lukashova, V., Benovic, J. L., Carlson, K. E., Hunt, S. W., & Bouvier, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312515110 · Cited by 173
“Although the precise mode of action is not completely understood, it is believed that pepducins bind to their target receptors and allosterically modulate their signaling activity (2, 3).”
BackgroundAllostery and biased agonism at class B G protein-coupled receptors
Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00049 · Cited by 112
Molecular mechanisms regulating Proteinase-Activated Receptors (PARs)
Chandrabalan, A., & Ramachandran, R. (2021) · The FEBS Journal · doi:10.1111/febs.15829 · Cited by 83
Melanocortins, Melanocortin Receptors and Multiple Sclerosis
Lisak, R., & Benjamins, J. (2017) · Brain Sciences · doi:10.3390/brainsci7080104 · Cited by 27
Metadata
- Authors
- O'Callaghan, K., Kuliopulos, A., & Covic, L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 287
- Issue
- 16
- Pages
- 12787-12796
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2067856993
- Cited by
- 157
- References
- 6
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.